Mubritinib (TAK-165) is a
protein kinase inhibitor which was under development by
for the treatment of
cancer
Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. These contrast with benign tumors, which do not spread. Possible signs and symptoms include a lump, abnormal b ...
.
It completed
phase I clinical trial
Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, diet ...
s but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.
See also
*
Protein kinase inhibitor
References
{{Growth factor receptor modulators
Tyrosine kinase inhibitors
Oxazoles
Triazoles
Trifluoromethyl compounds
Abandoned drugs